
|Articles|January 1, 2003
Injectable Silicone Shows Promisefor Treatment of HIV-associated Facial Lipoatrophy
Chicago -- Off-label experience using injectable silicone (Silikon 1000) in an investigational protocol indicates it is a highly effective and, thus far, very safe modality for treating facial lipoatrophy in HIV-infected patients, Derek H. Jones, M.D., said at the annual meeting of the American Society for Dermatologic Surgery.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











